27 January 2023 | News
This work was funded by the Health Research Council of New Zealand
image credit- shutterstock
The age-old quest for immortality has taken a step forward with the results of a New Zealand study recently published by the researchers at the University of Auckland.
The trial demonstrates that long-term treatment of healthy mice from middle-age (one year) with a drug currently used to treat cancer can increase their lifespan by an average of ten percent to around three years.
In this study, mice were fed a control diet or the same diet with the addition of a drug called alpelisib. Not only did the mice fed the drug containing diet live longer, they showed some signs of being healthier in old age such as improved coordination and strength.
However, the researchers are cautious about application to humans since the mice treated with the drug also had some negative markers of ageing like lower bone mass.
“Ageing is not only about lifespan but also about quality of life,” says research fellow Dr Chris Hedges. “Therefore, we were pleased to see this drug treatment not only increased longevity of the mice but they also showed many signs of healthier ageing. We are working now to understand how this happens.”
Principle investigator Associate Professor Troy Merry says: “We are not suggesting that anyone should go out and take this drug long-term to extend lifespan, as there are some side effects. However, this work identifies mechanisms crucial to ageing that will be of use in our long-term efforts to increase lifespan and health-span. It also suggests a number of possible ways in which shorter term treatments with this drug could be used to treat certain metabolic health conditions and we are following this up now.”
Professor Peter Shepherd says that alpelisib targets an enzyme called PI 3-kinase.